5 Key Takeaways

• 1

  CTMC has cleared 10 investigational new drug applications with biotech and academic partners, and some supported first-in-human studies have reported complete responses.

• 2

  CTMC aims to integrate clinical insight, manufacturing, analytics, regulatory strategy, and biotech partnerships from the start to support therapy development and scale-up.

• 3

  Obsidian’s OBX-115, an engineered tumor-infiltrating lymphocyte therapy, received initial IND and first-in-human clinical translation support from CTMC and MD Anderson.

• 4

  Bock identifies commercial scalability as the cell and gene field’s biggest bottleneck, citing manufacturing that can be slow, costly, variable, labor-intensive, or difficult to deliver reliably.

• 5

  He advocates designing cell therapies and manufacturing processes for scale, using closed systems, robotics, automation, integrated analytics, digital batch records, and process control.